

## Validation of a point-of-care testing for Dengue NS1 antigen, a Brazilian endemic disease

Halanna de Paula Riedi<sup>1\*</sup>, Gabriele Luise Neves Alves<sup>2</sup>, Matheus Gonçalves Severo<sup>2</sup>, Lucca Centa Malucelli<sup>2</sup> and Carolina Melchioretto dos Santos<sup>2</sup>

- 1) Scientific Research Department, Hilab Campus, José A. Possebom, 800, Curitiba-PR (Brazil), 81270-185
- 2) Validation Department, Hilab Campus, José A. Possebom, 800, Curitiba-PR (Brazil), 81270-185

\*e-mail: halanna.riedi@hilab.com

Keywords: validation, dengue, point-of-care-testing.

## **ABSTRACT**

Dengue is a mosquito-borne viral infection widespread throughout the tropics. According to WHO¹, 1,465,243 dengue cases were reported in Brazil in 2020, with an incidence rate of 702.77 cases per 100,000 population and 554 deaths. Numbers are often under-reported, since the majority of cases are asymptomatic, mild or self-managed, similar to other febrile illnesses. Dengue NS1 antigenemia is a risk factor associated with severe disease². Therefore, it is important to provide a reliable point-of-care testing (POCT) for screening dengue at the onset of symptoms, especially far from urban centers. In this study we compared the Hilab Dengue NS1 Antigen POCT to the gold-standard methodology for dengue NS1 diagnosis. Our POCT showed a Kappa index of 1.00 (95% CI: 0.86-1.00), suggesting a high agreement between methods, validating the efficiency of the test (Table 1).

Table 1: Dengue NS1 Antigen POCT Clinical Evaluation

Clinical Evaluation		Gold-Standard Laboratory Immunochromatography		Total
		Positive	Negative	
Hilab Dengue NS1 Antigen POCT	Positive	40	0	40
	Negative	0	85	85
Total		40	85	125
Relative Sensitivity		>99%	95% CI: 90%-100%	
Relative Specificity		>99%	95% CI: 95%-100%	
Cohen's Kappa index (k) = 1.00 (95% Cl: 0.86 - 1.00) Cl: Confidence Interval				

## **ACKNOWLEDGEMENTS**

The authors thank the Hilab Laboratory for financially supporting this work.

## REFERENCES